ABSTRACT
INTRODUCTION
During the past few decades mitral valve repair has become the procedure of choice for treatment of mitral regurgitation (MR) because of advantages such as low rates of thromboembolism, resistance to endocarditis, excellent late durability reported to be as long as 25 years, and no need for anticoagulation in the majority of patients [Fedak 2008 ]. Because of these advantages, the threshold for performing valve repair has been lowered to include even asymptomatic patients, given that successful repair is likely for a high percentage of patients [Bonow 2006; Fedak 2008] . Mitral valve repair in valves damaged by rheumatic heart disease (RHD) is a different situation, however. In rheumatic mitral valves, unlike ischemic and degenerative valves, mitral stenosis (MS) and MR are always associated with lesions on the affected valves. For this reason, rheumatic mitral valve repair is a technically demanding procedure [Duran 1991; Erez 2003 ]. Reports of mitral valve repair with acceptable results in RHD patients have been published, however [Choudhary 2001; Kumar 2006] . In some mitral valve lesions stenosis is more extensive than regurgitation, whereas in other lesions regurgitation is more extensive. Therefore we retrospectively investigated the results of mitral valve repairs in a population of RHD patients with pure regurgitation and mixed mitral valve lesions.
PATIENTS AND METHODS
The study was approved by the institutional ethics committee. We retrospectively reviewed the charts of patients who underwent mitral valve procedures during the period of January 1998 through January 2008. A total of 173 patients with a defi nitive diagnosis of RHD were included in study. Patients who had undergone valve repair surgery, treatment for RHD in childhood, or received prophylactic antibiotic therapy for RHD up to the age of 21 years were included in the study. Patients without a history of RHD and consequent treatments were excluded.
The patients were grouped according to their mitral valve pathology. Preoperative transthoracic and transesophageal echocardiography examinations were performed on all patients. Patients were divided into 2 groups according to the transvalvular mitral gradient in the preoperative echocardiographic evaluation. The gradient was greater than 5 mm Hg in the MS/MR group and less than 5 mm Hg in the MR group. In the MS/MR group there were 82 patients with mixed MS and MR and the mean transvalvular mitral gradient in the preoperative echocardiography was 8.42 ± 2.14. In the MR group, 91 patients had pure mitral regurgitation and the mean transvalvular mitral gradient in preoperative echocardiography was 1.89 ± 1. Preoperative patient characteristics are listed in Table 1 . The concomitant valvular pathologies are reported in Table 2 . Data regarding structural deterioration, nonstructural dysfunction, valve thrombosis, embolism, bleeding events, prosthetic valve endocarditis, reoperation, and all valve-related morbidity and mortality were included in the study.
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Selection and Decision for Repair
Both preoperative echocardiographic examination results and intraoperative observations were used to determine the mitral valve repair procedure. In the preoperative echocardiographic examination, the pliability of leafl ets and the amount of calcifi cation and extent of valve involvement were used for patient selection for valve repair. The decision for repair surgery was conducted during surgery after visual inspection of the valve and subvalvular structures. During the surgery, the absence or presence of heavy fi brosis and calcifi cation of the subannular chordal structure were used to determine whether to perform mitral valve repair or not.
Operative Techniques
All of the operations in both groups were performed while patients were on cardiopulmonary bypass with moderate hemodilution and moderate hypothermia (32°C). Continuous retrograde blood cardioplegia was used for myocardial protection. The mitral valve lesions and, if present, the tricuspid and/or aortic valve diseases were initially evaluated through a left and, if necessary, right atriotomy. A careful analysis of the anatomic and functional valvular lesions was completed to ensure that the decision for repair was correct. We attempted reconstruction if restoration of cusp mobility, shape, and central apposition was deemed feasible.
Factors that infl uenced the valvuloplasty procedures were severe chordal thickening, funnel degeneration of the subvalvular apparatus, destructive leafl et calcifi cation, severe posterior leafl et retraction, nonpliable aortic cusps, irregular fi brotic thickening of cusps, bicuspid aortic valve, and laceration during unrolling of cusp edge. Appropriate reconstructive techniques were applied in accordance with the intraoperative fi ndings. The mitral valve was repaired fi rst and if necessary the repair was followed by reconstruction of the aortic valve and/or tricuspid valve repair.
Mitral valvuloplasty techniques included annuloplasty, augmentation of the posterior leafl et by extension with autologous pericardium, release of retracted subvalvular apparatus, and the restriction of increased mitral valve mobility by quadrangular resection of posterior leafl et, shortening of elongated chordae, or chordaplasty.
Mitral annuloplasty techniques consisted of prosthetic ring annuloplasty, Kay annuloplasty, Wooler and modifi ed annuloplasty techniques (modifi ed posterior suture annuloplasty similar to DeVega tricuspid annuloplasty). The mobilization of mitral leafl ets was achieved by commissurotomy, fenestration of fused chordae, and chordal and/ or papillary splitting. Retraction of the posterior leafl et was released by enlargement with a crescendate-shaped glutaraldehyde-treated pericardial patch. The excessive mobility of mitral leafl ets was restricted with quadrangular resection and chordal transferring and shortening. Elongated chordae tendinae were buried into the tip of the papillary muscles with a pledgeted suture. Aortic valvuloplasty techniques were used in selected cases. Concomitant tricuspid valve surgery was required in 64 patients (37.0%) who had tricuspid insuffi ciency. The reconstructive procedures are shown in Table 3 . The concomitant procedures are listed in Table 4 . Th e Heart Surgery Forum #2009-1109
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Patient Follow-up All of the patients were evaluated with transthoracic echocardiography before they were discharged. Patient follow-up was performed in our outpatient clinic and with phone interviews. During the follow-up of patients, valverelated complications, reoperation, and New York Heart Association (NYHA) class were evaluated. Accurate valve analysis was achieved by transthoracic echocardiography in all patients. All of the patients received low-dose aspirin therapy postoperatively. Anticoagulation with warfarin was used in 66 patients who had left atrial thrombus and/or thromboembolic events, giant left atrium and atrial fi brillation, or aortic valve replacement with a prosthetic valve.
Statistical Methods
The occurrence of clinical outcomes during follow-up period was characterized by Kaplan-Meier survival curves.
Results are presented as mean ± standard deviation. To analyze the results of the valvular reconstruction procedures, we used a t-test for independent samples for continuous variables 
RESULTS
In our institution, during the period of 1998 through 2008, 2745 mitral valve operations were performed. During the same period, 1654 patients had mitral valve replacement secondary to rheumatic heart disease, and a total of 529 patients had reconstruction surgery. In this study, data fi les for 173 patients with rheumatic mitral valve disease who had reconstructive surgery were thoroughly evaluated.
Overall hospital mortality was 2.3% (4 patients; 3 in group MR and 1 in group MS/MR). The reasons of mortality were failure of reconstruction and early reoperation in 3 patients and development of low cardiac output in 1 patient. The mortality and postoperative follow-up parameters are summarized in Table 4 .
The total follow-up time was 4.0 ± 2.4 years (range 0.1-10.7 years). There was no signifi cant difference between the follow-up durations of the groups (3.7 ± 2.5 years in group MR and 4.4 ± 2.3 years in group MS/MR; P = .056). The cumulative survival rates were 96.6% ± 1.9%, 93.3% ± 3.0%, and 93.3% ± 3.0% for 1, 5, and 10 years, respectively, in group MR and 97.6% ± 1.6%, 97.6% ± 1.6%, and 94.4% ± 3.6% in group MS/MR (log rank; P = .422) (Figure 1 ).
There were no thromboembolic or anticoagulant-related complications in both groups except for 1 patient. In group MR, a patient with history of mitral valve replacement underwent surgery 6 months later, developed infective endocarditis, and subsequently died from embolic stroke.
Reoperation was required in 11 (12.08%; 6 early and 5 late) patients in group MR and in 8 patients in group MS/ MR (9.7%; 7 early and 1 late), and the difference was not signifi cant (P = .685). Variables in both groups are listed in Table 4 .
Aortic valve replacement was performed on 25 patients (Table 3) . As shown in Table 3 , 4 patients in group MR and 7 patients in group MS/MR required aortic reconstruction along with aortic valve replacement. One patient in group MR required a fl anged modifi cation of a Bentall de Bono procedure for ascending aortic aneurysm and aortic regurgitation. Concomitant procedures were coronary artery bypass graft in 11 patients (6.4%), radiofrequency ablation in 6 (3.5%), patent foramen ovale closure in 3 (1.7%), primary atrialseptal defect repair in 2 (1.1%), fl anged Bentall de Bono procedure in 1 (0.6%), left anterior descending branch of left coronary artery-pulmonary artery fi stula repair in 1 (0.6%), and ecortications of the right pleura in 1 (0.6%). Freedom from reoperation was 92.0% ± 2.9% and 85.4% ± 4.2% at the fi rst and fi fth years in group MR and 91.8% ± 0.3% and 90.6 ± 3.2% in group MS/MR (log-rank; P = .464) (Figure 2) .
The late mortality rate was 2.1% (in 2 patients) in group MR and 2.4% (in 2 patients) in group MS/MR. The causes of late mortality included heart failure in 1 patient and stroke in 1 patient in group MR and mediastinitis in 1 patient and sepsis and multiorgan failure in 1 patient in group MS/MR.
DISCUSSION
Repair of the mitral valve is well known for its effi cacy, durability, and avoidance of many complications [Kumar 1995] . As experience grows in this fi eld, surgeons try to repair more valves in RHD patients. Our study evaluates our 10 years of experience and results on mixed valve pathologies, which have not previously been studied extensively.
Choudhary and colleagues, who have published one of the biggest series in RHD patients, analyzed RHD patients who have had mitral repairs. They investigated mitral pathologies (including chordal elongation and annular dilatation) along with isolated and mixed valve lesions [Choudhary 2001] . Unlike Choudhary et al, we used valvular and subvalvular procedures as explanatory variables to investigate their effects on patient outcomes.
The postoperative mortality in our study was similar to that reported for other studies [Choudhary 2001; Kumar 2006] . Choudhary and colleagues [Choudhary 2001 ] reported their experience on 818 patients and their fi nding that left ventricular disease, preoperative congestive heart failure, and NYHA class IV are risk factors for mortality. In our analysis, we found only subvalvular reconstructions to be related to mortality. This difference can be explained by the more aggressive nature of the disease in our patients, who may have had more advanced disease.
Despite many signifi cant improvements in cardiac surgical techniques, the operative risk for combined aortic and mitral valve surgery is still more than 5% [Bozbuga 2003 ]. Use of any mechanical valve exposes the patient to an incremental risk of thromboembolism and anticoagulantion-related complications. In addition, prophylactic valve replacement should not be the treatment of choice for moderate valve disease, especially in patients with other predominant valve diseases [Bernal 1998 ]. Thromboembolism and bleeding are the most frequently reported valve-related complications. The overall linearized rate for embolism in published series has ranged from 0.5% to 3.5% [Erez 2003 ]. Valvuloplasty has clear advantages over prosthetic replacement. All repair procedures carry a low operative risk [Bozbuga 2003 ]. The advantages of valve reconstruction include reduced need for an anticoagulant regimen. 
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In patients with rheumatic mitral-aortic valve disease, the procedure of valvuloplasty might have less durability however, because the need for an anticoagulation regimen is reduced [Bozbuga 1997; Bozbuga 2003; Kumar 2006] . Progression of disease is the most important risk factor for reoperation. Early failure of the valvuloplasty is often attributable to technical factors. In an editorial paper by Adams and Anyanwu, the authors discuss the recurrent regurgitation [Adams 2006 ]. In the transesophageal echocardiography study performed after surgery, the surgeon should confi rm competent valve function; residual failure may lead to a progressive valvular failure and then to ventricular dysfunction. We had about 85% success postoperatively in both groups, and 13 patients from each group had grade 3 or 4 regurgitation. Thirteen patients (6 in group MR and 7 in group MS/ MR) underwent reoperation before discharge. The higher use of inotropes in group MS/MR may be explained by the lower preoperative ejection fractions in this group (Table 1) .
Valvular repair procedures may not fully restore valve competence. Even though we confi rmed valvular competence with transesophageal echocardiography after surgery, we observed relatively high regurgitation degrees and reoperation rates. Kumar and colleagues successfully performed valve repair in RHD patients [Kumar 2006 ]. Our study demonstrated similar rates of procedures (annuloplasty, commissurotomies) and high success rates in this population of patients. One of the major fi ndings of our study is the fact that mixed lesions of the mitral valve may be repaired as effi ciently as purely regurgitant valves, with similar postoperative success rates. In our study, both patient groups had low morbidity and mortality, and reoperation rates did not differ.
The major limitation of the present study is that most of the information was collected retrospectively. Another limitation was the inclusion of the patients who underwent various reparative procedures due to the various intraoperative fi ndings. This is a common problem for surgical studies because randomization is a hard goal to achieve.
In conclusion, we demonstrated that valve repair can be performed for mixed MS/MR patients with results similar to those in pure MR patients. The postoperative MR, reoperation, and mortality rates were similar. The type of mitral valve pathology does not affect postoperative mortality or morbidity.
